ArticleFood science & nutrition2025
Resveratrol Relieves Hepatic Steatosis and Enhances the Effects of Atorvastatin in a Mouse Model of NAFLD by Regulating the Renin-Angiotensin System, Oxidative Stress, and Inflammation.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated multi‑omics analysis of liver metabolic dysregulation in ACE2 knockout mice.International journal of molecular medicine · 2025Article
- Biochemical and molecular evaluation of resveratrol and selenium nanoparticles in managing type 2 diabetes and its complications.Scientific reports · 2025Article
- Effect of resveratrol on key signaling pathways including SIRT1/AMPK/Smad3/TGF-β and miRNA-141 related to NAFLD in an animal model.Research in pharmaceutical sciences · 2025Article
- Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classical renin-angiotensin system (RAS) axis is implicated in NAFLD development by promoting oxidative stress and inflammation, whereas the nonclassical axis antagonizes its effects. In the present study, we evaluated the effects of resveratrol (RSV), a polyphenol antioxidant, alone and in combination with atorvastatin (AT) on the RAS axes in NAFLD mice. Male C57/BL6 mice were fed a normal diet (control group) or a high-fat diet (HFD) for 12 weeks to induce NAFLD. Afterwards, the animals received AT (20 mg/kg), RSV (100 mg/kg/day), and AT + RSV (20 and 100 mg/kg/day) by oral gavage for 4 weeks. NAFLD animals exhibited swollen hepatocytes with numerous fat-containing vacuoles. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were increased in NAFLD mice. Additionally, HFD mice exhibited dyslipidemia, as manifested by increased cholesterol (Chol), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C). HFD significantly increased oxidative stress, as manifested by high levels of malondialdehyde and low paraoxonase 1 activity. Additionally, NAFLD mice showed significantly increased IL-1β, IL-6, and TNF-α expression and reduced IL-10 expression. An imbalance among RAS axes was evident as high expression levels of angiotensinogen, renin, and type 1 angiotensin receptor and reduced expression levels of angiotensin-converting enzyme 2 and angiotensin 1-7. RSV ameliorated these changes in NAFLD mice, which were comparable with the beneficial effects of AT. Interestingly, the ameliorative effects of AT increased considerably when it was administered in combination with RSV. Overall, our findings indicate that RSV attenuates HFD-induced NAFLD in mice, particularly when co-administered with AT, at least by regulating the RAS axes, oxidative stress, and inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.